ArticleInternational journal of women's health2010
Clinical trials and progress with paclitaxel in ovarian cancer.
Article in International journal of women's health, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 100 citations in OpenAlex.
- Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis.Journal of multidisciplinary healthcare · 2025Article
- Polycaprolactone-Vitamin E TPGS Micellar Formulation for Oral Delivery of Paclitaxel.Polymers · 2024Article
- Characteristics of wild hazelnut populations in Northeast China and selection of superior provenances.PloS one · 2024Article
- Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.Molecular pharmaceutics · 2023Article
- Five Species ofGenes · 2022Article
- Clinical translation of immunomodulatory therapeutics.Advanced drug delivery reviews · 2021Review
- Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.PloS one · 2021Article
- Mechanisms of Taxane ResistanceCancers · 2020Review
- Personalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome.JCO clinical cancer informatics · 2020Article
- Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings.Journal of Alzheimer's disease reports · 2019Review
- The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane.Cancers · 2019Article
- Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel.International journal of molecular sciences · 2019Article
- Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model.Cancers · 2019Article
- MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.Neoplasia (New York, N.Y.) · 2019Article
- Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.Cellular and molecular life sciences : CMLS · 2019Review
- Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression.Oncotarget · 2019Article
- Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery.Marine drugs · 2019Article
- Article
- Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer.Vivechan international journal of research · 2018Article
- Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.Molecular therapy. Nucleic acids · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel is a front-line agent for ovarian cancer chemotherapy, along with the platinum agents. Derived from the Pacific yew tree, Taxus brevifolia, paclitaxel has covered significant ground from the initial discovery of its antineoplastic properties to clinical applications in many forms of human cancers, including ovarian cancer. Although much has been published about the unique mechanism of action of this agent, several issues remain to be resolved. Finding the appropriate dosage schedule for paclitaxel in chemo-naïve and recurrent ovarian cancer, defining the role of paclitaxel in maintenance chemotherapy, and elucidating the mechanisms of taxane resistance are areas of intense research. Newer forms of taxanes are being manufactured to avoid troublesome adverse effects and to improve clinical efficacy. These issues are reviewed in detail in this paper with an emphasis on clinically relevant evidence-based information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.